NCT04343586 is a NA clinical trial of Blue light phototherapy in Grover's Disease, sponsored by Northwestern University.

Who is sponsoring NCT04343586?

NCT04343586 is sponsored by Northwestern University.

What drugs are being tested in NCT04343586?

Interventions in NCT04343586: Blue light phototherapy.

What condition does NCT04343586 study?

NCT04343586 studies Grover's Disease, Psoriasis Vulgaris.

Is NCT04343586 still recruiting?

NCT04343586 is currently completed. Last updated 17 March 2023.

Are results published for NCT04343586?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2023-03-17 · How we verify

NCT04343586

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Blue Light Phototherapy

Completed NA Results posted Last updated 17 March 2023

What this trial tests

NA trial testing Blue light phototherapy in Grover's Disease in 11 participants. Completed in 22 September 2022.

Timeline

1 September 2020

Primary endpoint
20 December 2021

22 September 2022

Quick facts

Lead sponsor	Northwestern University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	11
Start date	1 September 2020
Primary completion	20 December 2021
Estimated completion	22 September 2022
Sites	1 location across United States

Drugs / interventions tested

Blue light phototherapy

Conditions studied

Grover's Disease — all drugs for Grover's Disease →
Psoriasis Vulgaris — all drugs for Psoriasis Vulgaris →

Sponsor

Northwestern University

Who can join

Adults 18 to 89, any sex, with Grover's Disease or Psoriasis Vulgaris. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Efficacy of Blue Light Therapy for Patients With Grover's Disease Primary · Time Frame: 5 weeks

Demonstrate preliminary skin efficacy as measured by lesion count

Baseline

Group	Value	95% CI
Adult Treatment Arm	27	9.2 – 45.6

End of Treatment

Group	Value	95% CI
Adult Treatment Arm	6	2.5 – 8.7

Assess User Experience With the Dermatology Life Quality Index (DLQI) Pre and Post-treatment. Primary · Time Frame: 5 weeks

The DLQI is a questionnaire with 10 questions. The maximum score is 30 and minimum is 0. The higher the score, the more quality of life is impaired.

Baseline

Group	Value	95% CI
Adult Treatment Arm	4.3	1.3 – 7.4

End of Treatment

Group	Value	95% CI
Adult Treatment Arm	2.3	1.3 – 3.4

Sponsor's own description

This study will use Blue-light Photo-therapy to treat patients with psoriasis vulgaris and Grover's Disease.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Assessment of Blue Light Phototherapy for Grover Disease: A Nonrandomized Controlled Trial.
Olagbenro M, Ravi S, Myers D, Lin D, et al · · 2023 · cited 1× · PMID 36449285 · DOI 10.1001/jamadermatol.2022.4491

Verify or expand the search:

Other trials of Blue light phototherapy

Trials testing the same drug.

NCT02431494 — Safety and Preliminary Efficacy of Combination Therapy for the Treatment of Acne Vulgaris · NA · terminated

Other Northwestern University trials

Trials by the same sponsor.

NCT06545695 — Epidermal Growth Factor Receptor Inhibition for Keratinopathies · Phase 1, PHASE2 · not yet recruiting
NCT07261657 — N-803 in Patients With Progressive Synovial Sarcoma and Myxoid/Round Cell Liposarcoma Previously Treated With Adoptive C · EARLY_PHASE1 · not yet recruiting
NCT07392775 — ALDH2 Genetic Testing in East Asian Community · NA · not yet recruiting
NCT06886776 — Implementing A Secure Firearm Storage Program in Illinois Health Centers in Partnership With AllianceChicago and the Ill · NA · not yet recruiting
NCT07469176 — Co-Designing and Evaluating Additional Mothers and Babies Program Content for Expectant and New Parents of Children With · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04343586 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Northwestern University
Last refreshed: 17 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04343586.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing